Chemical castration and anti-androgens induce differential gene expression in prostate cancer

Journal of Pathology

Volumn 227, Issue 3, 2012, Pages 336-345

  Lehmusvaara, Saara ^a   Erkkilä, Timo ^a   Urbanucci, Alfonso ^a   Waltering, Kati ^a   Seppälä, Janne ^a   Larjo, Antti ^a   Tuominen, Vilppu J ^a   Isola, Jorma ^a   Kujala, Paula ^b   Lähdesmäki, Harri ^c   Kaipia, Antti ^a   Tammela, Teuvo L J ^a   Visakorpi, Tapio ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c AALTO UNIVERSITY   (Finland)

Author keywords

Endocrine therapy; LHRH; Neoadjuvant; Neoplasia; Prostatic; TMPRSS2 ERG

Indexed keywords

BICALUTAMIDE; GOSERELIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ERG GENE; FUSION GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GOLD STANDARD; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TMPRSS2 GENE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BAYES THEOREM; CASTRATION; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FINLAND; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84862018113     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4027     Document Type: Article

References (41)

1. Labrie F, Belanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361-379. (Pubitemid 40686649)
2. Huggins C, Hodges CV Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
3. Auclair C, Kelly PA, Labrie F, et al. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun 1977; 76: 855-862. (Pubitemid 8130879)
4. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-577. (Pubitemid 30171897)
5. Parmar H, Phillips RH, Lightman SL, et al. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 1985; 2: 1201-1205. (Pubitemid 16203839)
6. Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 2006; 28: 1485-1508. (Pubitemid 44841984)
7. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-456. (Pubitemid 28251992)
8. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164: 1579-1582.
9. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
10. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-461. (Pubitemid 36359626)
11. Palmberg C, Koivisto P, Visakorpi T, et al. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 1999; 36: 191-196. (Pubitemid 29381303)
12. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17: 1649-1657.
13. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
14. Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
15. Halabi S, Vogelzang NJ, Ou SS, et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009; 27: 2766-2771.
16. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
17. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
18. Tuominen VJ, Isola J. The application of JPEG2000 in virtual microscopy. J Digit Imaging 2009; 22: 250-258.
19. Erkkilä T, Lehmusvaara S, Ruusuvuori P, et al. Probabilistic analysis of gene expression measurements from heterogeneous tissues. Bioinformatics 2010; 26: 2571-2577.
20. Tolonen TT, Kujala PM, Laurila M, et al. Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. Hum Pathol 2011; 42: 1635-1642.
21. Saramäki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
22. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33: W741-748. (Pubitemid 44530021)
23. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69: 8141-8149.
24. Urbanucci A, Sahu B, Seppälä J, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2011; [Epub ahead of print doi: 10.1038/onc.2011.401.]
25. Massie CE, Lynch A, Ramos-Montoya A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011; 30: 2719-2733.
26. He HH, Meyer CA, Shin H, et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010; 42: 343-347.
27. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837. (Pubitemid 46802390)
28. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033-5041. (Pubitemid 46910214)
29. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-227. (Pubitemid 38364606)
30. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39: 311-318. (Pubitemid 46328487)
31. Gery S, Sawyers CL, Agus DB, et al. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002; 21: 4739-4746. (Pubitemid 34879449)
32. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004; 64: 3814-3822. (Pubitemid 38697290)
33. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99: 11890-11895. (Pubitemid 34994494)
34. Shanmugam I, Cheng G, Terranova PF, et al. Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ 2007; 14: 2085-2094. (Pubitemid 350131158)
35. Hayes SA, Zarnegar M, Sharma M, et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 2001; 61: 2112-2118. (Pubitemid 32692035)
36. Glynne-Jones E, Harper ME, Seery LT, et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001; 94: 178-184. (Pubitemid 32911410)
37. Wang R, Xu J, Mabjeesh N, et al. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res 2007; 13: 6040-6048. (Pubitemid 350075060)
38. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8: 871-878. (Pubitemid 350001432)
39. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-825. (Pubitemid 351809667)
40. Barwick BG, Abramovitz M, Kodani M, et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010; 102: 570-576.
41. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110. (Pubitemid 351439472)